title: Effect of Fluid Status at Week 12 on Visual and Anatomic Outcomes at Week 52 in the VIEW 1 and 2 Trials.
abstract: OBJECTIVE
  To evaluate effect of retinal fluid status at week 12 on visual and anatomic outcomes at week 52 in patients with neovascular age-related macular degeneration from the VIEW studies.
  
  
  METHODS
  Post-hoc analysis included 1,465 eyes treated with intravitreal aflibercept (Eylea; Regeneron, Tarrytown, NY) 2 mg every 4 weeks (2q4) or every 8 weeks following three initial monthly injections (2q8) or ranibizumab (Lucentis; Genentech, South San Francisco, CA) 0.5 mg every 4 weeks (Rq4), which had known retinal fluid status at weeks 12 and 52.
  
  
  RESULTS
  At 12 weeks, 512 (35%) eyes had fluid and 953 (65%) were fluid-free. Two hundred three (41.5%), 148 (29.8%), and 161 (33.5%) eyes had fluid in Rq4, 2q4, and 2q8, respectively. Best-corrected visual acuity (BCVA) change at week 52 from baseline was independent of retinal fluid status at week 12 or treatment assignment. Eyes were more likely to remain fluid-free at week 52 if absent of fluid at week 12.
  
  
  CONCLUSIONS
  At week 52, 2q4, 2q8, and Rq4 improved BCVA independent of fluid status at week 12.
authors.forename: Darius M
authors.initials: DM
authors.lastname: Moshfeghi
authors.forename: Seenu M
authors.initials: SM
authors.lastname: Hariprasad
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Marx
authors.forename: Desmond
authors.initials: D
authors.lastname: Thompson
authors.forename: Yuhwen
authors.initials: Y
authors.lastname: Soo
authors.forename: Andrea
authors.initials: A
authors.lastname: Gibson
authors.forename: Namrata
authors.initials: N
authors.lastname: Saroj
authors.forename: Robert
authors.initials: R
authors.lastname: Vitti
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Heier
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D000069579:Ranibizumab / Q000009:adverse effects / Q000627:therapeutic use*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D012160:Retina / Q000473:pathology; D058471:Subretinal Fluid / Q000187:drug effects* / Q000502:physiology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D057135:Wet Macular Degeneration / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D020533:Angiogenesis Inhibitors; D004338:Drug Combinations; D011993:Recombinant Fusion Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab